Current and future immunotherapies for NSCLC
Abstract Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors targeting the PD-1/PD-L1 and CTLA-4 axes have fundamentally transformed its treatment landscape. This narrative review traces the evolution of NSCLC immunotherapy...
Gardado en:
| Principais autores: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMC
2026-04-01
|
| Series: | Journal of Hematology & Oncology |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1186/s13045-026-01791-w |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|